title: Dynamic changes in the intrafollicular inhibin/activin/follistatin axis during human follicular development: relationship to circulating hormone concentrations.
abstract: Previous studies of normal human ovaries suggest that inhibins, activins, and follistatin (FS) are produced in a stage-specific pattern indicative of intraovarian, autocrine/paracrine roles in regulating follicle development. However, these studies relied largely on surgical specimens and thus include little information about the menstrual cycle stage or dominant follicle status at the time follicles or ovaries were obtained. The purpose of this study was to 1) determine the pattern of intrafollicular hormone biosynthesis across antral follicle development in normal women, 2) compare hormone concentrations in dominant and nondominant follicles from the same ovary, and 3) examine the relationship between dominant follicle hormone content and circulating hormone levels. Intrafollicular estradiol, progesterone, and inhibin A concentrations increased significantly with follicle size or maturity, whereas significant inverse relationships were observed for androstenedione and the androstenedione/estradiol (A:E) ratio. In contrast, neither inhibin B, activin A, nor free FS varied consistently with size or maturity. Estradiol, progesterone, and inhibin A levels and A:E ratio were significantly lower in nondominant follicles compared to the dominant follicle aspirated from the same ovary. Although intrafollicular and serum concentrations of each hormone followed the same general pattern as follicles develop, the human follicular fluid/serum gradients changed during the follicular phase and were different for estradiol and inhibin A, suggesting the presence of stage-specific differences in pharmacodynamics. These results are consistent with the hypothesis that the orderly transition from an activin-dominant to an inhibin A/FS-dominant microenvironment is critical for dominant follicle development.
authors.affiliation: Reproductive Endocrine Unit, National Center for Infertility Research, Massachusetts General Hospital, Boston, USA. schneyer.alan@mgh.harvard.edu
authors.forename: A L
authors.initials: AL
authors.lastname: Schneyer
authors.forename: T
authors.initials: T
authors.lastname: Fujiwara
authors.forename: J
authors.initials: J
authors.lastname: Fox
authors.forename: C K
authors.initials: CK
authors.lastname: Welt
authors.forename: J
authors.initials: J
authors.lastname: Adams
authors.forename: G M
authors.initials: GM
authors.lastname: Messerlian
authors.forename: A E
authors.initials: AE
authors.lastname: Taylor
mesh_terms: D028341:Activins; D000328:Adult; D000735:Androstenedione / Q000097:blood; D004958:Estradiol / Q000097:blood; D005260:Female; D038681:Follistatin; D006023:Glycoproteins / Q000097:blood / Q000378:metabolism*; D006133:Growth Substances / Q000097:blood / Q000378:metabolism*; D006801:Humans; D007265:Inhibins / Q000097:blood / Q000378:metabolism*; D007986:Luteinizing Hormone / Q000097:blood; D006080:Ovarian Follicle / Q000033:anatomy & histology / Q000502:physiology*; D010060:Ovulation / Q000502:physiology; D011374:Progesterone / Q000097:blood
chemical_list: D038681:Follistatin; D006023:Glycoproteins; D006133:Growth Substances; D028341:Activins; D000735:Androstenedione; D011374:Progesterone; D004958:Estradiol; D007265:Inhibins; D007986:Luteinizing Hormone